Vimal Sharma, MD
Internal Medicine · Richland, WANPI 1952468795
Payments from drug & device makers
Across 516 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Lilly USA, LLC$1K
- GSK$945
- Bayer$926
- Novo Nordisk$882
- AbbVie$688
- plus $3K from 30 others
What the payments were for
- Food & beverage$9,76699%
- Education$1401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 88 | $2,120 |
| Lilly USA, LLC | 67 | $1,060 |
| GSK | 60 | $945 |
| Bayer | 38 | $926 |
| Novo Nordisk | 62 | $882 |
| AbbVie(2 entities) | 40 | $688 |
| Pfizer | 23 | $441 |
| Mylan Specialty L.p. | 17 | $435 |
| Sanofi-aventis U.S. LLC | 14 | $292 |
| Novartis | 13 | $292 |
| Amgen | 10 | $268 |
| Otsuka America Pharmaceutical, Inc. | 14 | $241 |
| Boehringer Ingelheim | 9 | $173 |
| E.r. Squibb & Sons, L.L.C. | 9 | $165 |
| Esperion Therapeutics, Inc. | 7 | $127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $108 |
| Abbott | 6 | $104 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $70 |
| Biohaven Pharmaceuticals, Inc. | 3 | $57 |
| Viatris Specialty LLC | 2 | $57 |
| Merck | 3 | $54 |
| Teva Pharmaceuticals USA, Inc. | 2 | $51 |
| Exact Sciences | 2 | $48 |
| Eisai Inc. | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 2 | $33 |
| Radius Health, Inc. | 2 | $33 |
| Sunovion Pharmaceuticals Inc. | 2 | $24 |
| Grifols USA, LLC | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Electromed, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Alfasigma USA, Inc. | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,907 in reported general payments places this provider in the 95th percentile of 2,038 internal medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 52 | $80,598 |
| MounjaroTirzepatide | 38 | $64,626 |
| EliquisApixaban | 36 | $51,294 |
| TrulicityDulaglutide | 22 | $44,638 |
| FarxigaDapagliflozin Propanediol | 27 | $36,333 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $22,504 |
| JardianceEmpagliflozin | 21 | $20,823 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $18,217 |
| KerendiaFinerenone | 17 | $16,865 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $6,056 |
| Tamsulosin Hcl | 150 | $2,894 |
| Levothyroxine Sodium | 253 | $2,853 |
| Atorvastatin Calcium | 385 | $2,602 |
| Novolog FlexpenInsulin Aspart | 12 | $2,129 |
| Potassium Citrate ErPotassium Citrate | 25 | $1,961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,060 | $109,26460 claims |
| Novo NordiskOzempic | $882 | $80,59852 claims |
| PfizerEliquis | $441 | $51,29436 claims |
| AstraZenecaFarxiga, Symbicort | $2,120 | $42,38951 claims |
| GSKTrelegy Ellipta | $945 | $22,50427 claims |
| Boehringer IngelheimJardiance | $173 | $20,82321 claims |
| BayerKerendia | $926 | $16,86517 claims |
| AbbVieSynthroid | $688 | $1,00533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,038 internal medicine providers in Washington.
Other internal medicine in Richland
- Sabrina BenjaminOlympia$7.9M
- Ryan AhernSeattle$7.3M
- Eric KleinOlympia$2.4M
- Scott RamseySeattle$2M
- Vidya MenonTacoma$1.8M
- Peter ShalitSeattle$1.8M
- Yuan Po TuEverett$1.6M
- Peiqing QianSeattle$1.5M
- Radica AlicicSpokane$1.5M
- Shelly KhuranaLynnwood$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.